Grafa News and Videos — Page 282

Joby Aviation (NYSE:JOBY) announced that an aircraft equipped with its autonomy technology completed the first autonomous flight across the United States, covering 3,199 miles without control inputs from its onboard safety pilot.

AstraZeneca (NASDAQ:AZN) and Daiichi Sankyo received a positive recommendation from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) for Enhertu (trastuzumab deruxtecan) in the adjuvant treatment of adults with resected HER2-positive breast cancer.

Corcept Therapeutics (NASDAQ:CORT) received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommending approval of relacorilant combined with nab-paclitaxel for patients with platinum-resistant ovarian cancer.

Permian Basin Royalty Trust (NYSE:PBT) declared a September 2026 cash distribution of $0.019593 per unit, totaling $913,228.22, payable on October 15, 2026, to unitholders of record as of September 30, 2026.

Philip Morris International (NYSE:PM) increased its regular quarterly dividend by 8.8% to $1.60 per share, representing an annualized dividend rate of $6.40 per share.

Chanson International Holding (NASDAQ:CHSN) reported net income of $0.8 million for the six months ended June 30, 2026, compared with a net loss of $1 million in the same period a year earlier.

Abeona Therapeutics (NASDAQ:ABEO) announced that Ultragenyx Pharmaceutical received U.S. Food and Drug Administration approval for FAYUVI (rebisufligene etisparvovec-hopf), a gene therapy for Sanfilippo syndrome type A.

Santacruz Silver Mining (NASDAQ:SCZM) acquired a 500-tonne-per-day milling facility in Bolivia to process ore from its wholly owned subsidiary San Lucas and support expansion of its third-party ore-sourcing business.

MISTRAS Group (NYSE:MG) agreed to be acquired by affiliates of H.I.G. Capital for $20.35 per share in cash, representing an enterprise value of approximately $866 million including outstanding debt.

BlossomHill Therapeutics (NASDAQ:BLSM) reported second quarter 2026 financial results and pipeline progress, highlighting its strengthened cash position following an upsized initial public offering.